The European Investment Bank (EIB) has signed a €20 million loan with Overture Life to invest in automating assisted reproductive processes and using AI to improve IVF pregnancy outcomes and fertility preservation, according to the EIB. The agreement was signed during the Women Leaders in Life Science conference organized by the EIB Group as part of Bio-Europe in Vienna on November 4.
Access to assisted reproduction is a critical and growing issue amid declining birth rates globally. The EIB financing will support Overture Life’s R&D, manufacturing scale-up, and clinical trials, aiming to make IVF more effective and reduce bottlenecks. This includes supporting the commercialization in Europe of products like Overture Life’s DaVitri vitrification platform and non-invasive metabolomics-based predictive tools to enhance detection of embryos’ suitability for implantation in IVF.
Overture Life’s technology automates egg freezing and IVF procedures, increasing accessibility for women. The DaVitri platform includes a tabletop device that automates the vitrification (egg freezing and thawing) preparation of human mature oocytes, enabling egg freezing beyond throughput-constrained fertility clinics. It’s designed to integrate seamlessly with both existing and new embryology labs and is expected to contribute to increasing IVF access in Europe.
EIB Vice President Karl Nehammer says the bank is delighted to join forces with research-intensive startups like Overture to expand the range of healthcare and medical solutions available to European citizens. Hans Gangeskar, Overture Life’s CEO, says the funding is more than just financial support. “This is a signal that Europe understands the personal and demographic urgency of reproductive freedom,” he said.
The financing contributes to the EIB’s TechEU initiative to accelerate EU innovation and is backed by the InvestEU programme.
